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Abstract The aim of our study was to characterize the
association of clinical and genetic risk factors such as: ACE
genotype (rs17997552, rs1800764, rs4459609) and RGS2
(rs2746071) with the development of hypertension (HT) and
non-dipping phenomenon in patients with type 1 diabetes
mellitus (T1DM). A total of 238 adolescents and young
adults with T1DM—103 females and 135 males, aged
8–30 years (mean 17.35 ± 5.2) with diabetes duration
1–26 years (mean 7.72 ± 6.2), with mean HbA1c (IFCC)
58 ± 15 mmol/mmol—were subjected to 24-h ambulatory
blood pressure measurements (ABPM). The results of the
ABPM were analyzed in association with the polymorphisms
of ACE and RGS2 genes and clinical data of patients. HT was
recognized in 65 (27 %) and non-dipping in 111 (46.63 %)
patients. In the multivariate analysis of factors predisposing
to HT, the variables that remained significant were the fol-
lowing: male sex (OR 1.62; 95 % CI 1.171–2.250), non-
dipping (OR 1.40; 95 % CI 1.03–1.90) and total cholesterol
level (OR 1.01; 95 % CI 1.005–1.021). The only factor
influencing non-dipping was the duration of diabetes—OR
1.09 (95 % CI 1.04–1.14). The patients displaying non-dip-
ping have a twice increased risk of development of HT (OR
2.17; 95 % CI 1.21–3.89). There was no association between
disturbances of blood pressure (BP) and genotypes of ACE:
rs17997552, rs1800764, rs4459609 and RGS2: rs2746071.
Clinical rather than genetic risk factors seem to be connected
with BP disturbances in young patients with T1DM.
Although we have identified representative groups of HT
versus non-HT and dipping versus non-dipping subjects, the
effect of genetic predisposition to the development of higher
BP is too weak to be statistically significant.
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Despite improved methods of treatment and monitoring, type
1 diabetes mellitus (T1DM) still remains a disease with high
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risk of chronic micro- and macrovascular complications. One
of the most important risk factors contributing to these com-
plications is hypertension (HT). The most important tradi-
tional risk factors connected with the development of HT are
as follows: overweight/obesity, atherogenic lipid profile, and
in patients with diabetes, additionally the following: poor
glycemic control and long duration of diabetes [1, 2].
Genetic approaches may provide a powerful tool for
explaining the etiology and pathogenesis of HT. Many
studies in the previous years have confirmed that the genetic
variants of major components of the renin-angiotensin sys-
tem (RAS) are associated with higher blood pressure (BP),
myocardial infarction and lacunar stroke in non-diabetic
patients [3, 4]. In diabetic patients, especially children with
diabetes, the evidence is not clear. Some studies have shown
that different polymorphisms in angiotensin 1-converting
enzyme (ACE) gene are associated with development of
both persistent microalbuminuria and diabetic nephropathy
[5, 6]; however, other recently published reports have not
replicated these findings [7, 8]. Furthermore, a few studies
suggested an association between ACE genotype and ten-
dency to higher BP in normoalbuminuric, normotensive
patients during ABPM measurements in T1DM children [9,
10], but to date, there are no studies exploring this in ado-
lescents and young adults with HT and diabetes.
Additionally, BP homeostasis is very precisely regulated
through hormones and neurotransmitters activating G-pro-
tein-coupled receptors. These mechanisms control, among
other things, the diameter of resistance arterioles as well as
the electrolyte and fluid excretion rates in the kidney [11, 12].
Recently, a major regulator of G-protein signaling (RGS),
RGS2 protein, was identified and strongly associated with
HT. It was demonstrated that mice lacking RGS2 developed
strong HT and persistently increased vascular tone [11].
Subsequently, two studies described the hypertensive phe-
notype associated with RGS2 in humans, but there is no
evidence of its significance in patients with T1DM [13, 14].
The aim of our study was to characterize the association
of chosen clinical risk factors and genotypes with the
development of HT and non-dipping phenomenon in chil-
dren and young adults with T1DM. We hypothesized that
the genetic variations in the ACE genotype—insertion/
deletion (rs17997552), rs1800764, rs4459609—and RGS2
rs2746071 genotype could be connected with the regula-
tion of the BP and lead to its disturbances.
Methods
Study population
A total of 238 adolescents and young adults with T1DM—
103 females and 135 males, aged 8–30 years (mean
17.35 ± 5.2) with diabetes duration 1–26 years (mean
7.72 ± 6.2)—were included to the study. The study group
was very diverse in terms of age and diabetes duration to
assess the effect of genetic predisposition on developing
BP disturbances. The study protocol was approved by the
Local Ethics Committee. Informed consent was obtained
from the parents of children and/or from children
[16 years of age and adult patients themselves. The
patients were recruited from nearly 1,800 diabetic patients
regularly attending to the diabetic Outpatients Clinic in
Katowice or Lodz. The Department of Pediatrics, Pediatric
Endocrinology and Diabetology Medical University of
Silesia in Katowice and Department of Pediatrics, Oncol-
ogy, Hematology and Diabetology Medical University of
Lodz in Lodz are the regional referral centers for children
with T1DM. The centers are comparable with respect to
both the amount of patients (about 900 in each) and the
quality of diabetes care with the average of Hba1c about of
58 mmol/mmol for all patients [15]. The inclusion criteria
for the study were as follows: diabetes recognition con-
firmed by positive antibody tests and diabetes duration
above 1 year. The exclusion criteria were as follows: dia-
betic patients with other types of diabetes and other chronic
diseases.
Subjects were randomly selected for the study during the
routine annual check of diabetes care including blood tests
and ambulatory blood pressure measurements (ABPM). All
the patients were treated intensively by multiple injections
of short-acting regular insulin/analog and long-acting NPH/
long-acting analog insulin or by using insulin pumps. The
patients and their parents have been repeatedly educated in
diabetes care and have reached good/suboptimal long-term
glycemic control, as measured by mean HbA1c since dia-
betes onset until the end of the study. HbA1c was analyzed
as a continuous variable and as a dichotomous one, divided
on a[75 mmol/mol cutoff, in order to specifically evaluate
the impact of poor metabolic control.
Study protocol
After the formal clerking, basic blood tests were per-
formed. The information about the mean HbA1c [high-
performance liquid chromatography (HPLC) method], lipid
profile (enzymatic method) and daily insulin dose from the
last visit was used for statistical analysis. HbA1c assays
were performed by ion-exchange HPLC using the Bio-Rad
VARIANTTM Hemoglobin A1c Program (Bio-Rad Labo-
ratories, Inc. Hercules, California, USA). The VARI-
ANTTM Hemoglobin A1c Program has been certified by
the National Glycohemoglobin Standardization Programme
(NGSP) as meeting the DCCT standard. Reference values
for healthy people estimated by the local laboratory were
from 4.3 to 5.7 %. The within-run coefficient of variation
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(CV) determined by the manufacturer was 1.05 % for
normal patients and 0.94 % for diabetic patients; the
between-run CV was 1.61 and 1.16 % for normal and for
diabetic patients, respectively, as reported previously [16].
In all patients, the estimation of albumin excretion rate
(AER) was obtained from overnight urine sample. Micro-
albuminuria was defined as the presence of two consecu-
tive specimens with AER of [20 and \200 lg/min, as
recommended by International Society of Pediatric and
Adolescents Diabetes (ISPAD).
The 24-h ambulatory blood pressure measurements
(ABPM—Spacelabs Health, Model 90217, Hertford, UK)
were carried out in each patient based on the oscillometric
method with the appropriate cuff size. From 0600 to
2200 hours, BP was measured every 20 min and the night
measurements from 2200 to 600 hours were performed
every 30 min. Only records with a minimum 80 % of valid
measurements were taken into account. The norm values
were estimated individually for each adolescent based on
the sex, age and height percentile norm [17]. The means of
24-h BP, day period, night period and diurnal variations of
mean BP were calculated. HT was diagnosed when the
mean 24-h systolic pressure (SP) and diastolic pressure
(DP) was [95th percentile for sex, age and height of the
pediatric subject and [140/90 in adults according the
National High Blood Pressure Education Program Working
Group on High Blood Pressure in Children and Adoles-
cents [17]. Furthermore, diurnal variations of BP were
estimated and patients whose mean BP during the day
decreased by \10 % in the night were defined as non-
dipping. We verified the abnormal results: by the following
up another ABPM and by collecting the measurements
using the traditional oscillometric method performed in the
hospital and/or at home by patients/parents. Pubertal status
was evaluated using the Tanner stage, with a Tanner stage




A volume of 3 ml of peripheral blood was collected in
sterile tubes with anticoagulant 10 % EDTA (pH 8.0).
DNA was isolated using a commercially available kit
column AxyPrep Blood Genomic DNA Miniprep Kit
(Axygen, USA).
A volume of 250 ll of blood was added up to 500 ll
of Buffer AP1. The mixture was strongly shaken and then
added to 100 ll of AP2 buffer and centrifuged for
10 min. 12,0009g at room temperature. After centrifu-
gation, the supernatant was transferred to a column
miniprep, centrifuged and then washed with WIA Buffer
(700 ll) and twice with W2 Buffer (800 and 500 ll).
After drying column (12,0009g, 1 min), to elute the
genomic DNA, 200 ll of TE buffer was added and next
centrifuged 12,0009g for 1 min. The purified DNA was
stored at -20 C.
Analysis of the polymorphisms
Polymorphisms of genes implicated in BP regulation were
analyzed (Table 1). These polymorphisms were selected
for the study based on evidence from the literature. The
best known gene variant association in the ACE genes is
I/D variant, with allele DD connected with potentially
higher BP [4, 6, 9, 10]. Moreover, we chose to study
another two single nucleotide polymorphisms (SNP) of
ACE, rs1800764 and rs4459609, because they were shown
to characterize the haplotypic structure of ACE in European
populations [18, 19]. Additionally, we chose the hyper-
tensive phenotype of RGS2 gene described by Sugimoto
et al [12] in Japanese population to replicate their findings
in the Polish patients with DMT1.
Genotyping of polymorphic sites selected genes
For the analysis of three SNPs (ACE, RGS2), optimized
reagent system was used to study point mutations of
genes—TaqMan  SNP Genotyping Assays (Applied
Biosystems, USA). The reactions were carried out using an
Applied Biosystems thermocycler 7900HT Fast Real-Time
PCR, the 96-well plates in a volume of 5 ll. The compo-
nents of the reaction mixture of real-time PCR were, in
addition to fluorescent dye-labeled probe, appropriately
selected primers, DNA polymerase enzyme and the DNA
matrix. Moreover, the reaction buffer containing the
enzyme necessary for the working of metal ions and
diphosphates of deoxyribonucleotides (dNTPs) was added
to the mixture. ACE polymorphisms (insertion/deletion of
50 nucleotide pairs) were identified in horizontal electro-
phoresis in 2 % agarose gel using QantityOne software
(BioRad, USA).




transitions C ? T (C/T) at position




transitions A ? C (A/C) at position
-5,486 in the promoter sequence
rs4459609





transitions A ? G (A/G) at position
-638 in the promoter sequence
rs2746071
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Statistical analysis
Categorical data were compared using the chi-squared test
or, if the number of patients in any of the compared groups
was lower than five, using the two-tailed Fisher’s exact
test. Comparisons between two groups were performed
using Student’s t test. Analysis of variance was used for
comparisons of more than two groups. Multivariate anal-
yses were performed using logistic regression. Variable
selection was performed using backward stepwise model-
ing with a p value for variable exclusion of 0.15. Genetic
factors were forced to be retained in the model regardless
of significance in univariate analysis. A p value of \0.05
was considered as statistically significant.
Results
Based on ABPM records, HT was recognized in 65 (27 %)
patients, including persistent HT, recognized earlier treated
with hypertensive drugs (ACE inhibitors) in 9 patients and
HT as a new diagnosis in the remaining patients. The
characteristics of the subjects with and without HT are
shown in the Table 2. Subjects with HT were more fre-
quently male, had a longer duration of diabetes and had
worse lipid profiles with significantly higher levels of total
and LDL cholesterol and marginally higher triglyceride
levels. Subjects classified as having HT tended to be older
(however, this trend did not reach significance). We found
no differences in HbA1c, BMI, daily insulin dose and the
presence of microalbuminuria between the hyper- and
normotensive groups, which could have been a result of a
relatively good metabolic control in all of the studied
subjects.
Non-dipping was frequent in the studied group and was
reported in 111 (46.63 %) patients. Similarly, the analysis
of diurnal variables of BP showed that subjects with non-
dipping phenomenon were significantly older and had a
longer duration of T1DM. There were no associations
between dipping and other analyzed clinical parameters
(Table 2). Patients who did not display dipping showed a
twofold increase in risk of developing HT (OR = 2.17;
95 % CI 1.21–3.89).
There were no differences among ACE genotypes at all
three analyzed loci (rs17997552, rs1800764, rs4459609)
and RGS2 genotype (rs2746071) in terms of HT and
diurnal variations of BP. The distribution of the analyzed
loci in relation to HT and non-dipping are presented in the
Table 3.
We found no evidence of association between any of the
analyzed genotypes and percentages of abnormally high
SBP or DBP values for both day and night (Table 4).
In multivariate analysis of factors predisposing to HT,
the variables that remained significant were the following:
Table 2 Characteristics of the subjects: the whole group and subgroups: hypertension/normal BP and non-dippers/dippers concerning clinical
data and the results of the laboratory tests










F/M 103/135 20/45 83/90 0.01698 46/65 57/70 0.59
Age (years) 17.35 ± 5.20 18.67 ± 6.33 16.86 ± 4.62 0.094787 18.64 ± 5.49 16.22 ± 4.67 0.002172
Diabetes duration (years) 7.72 ± 6.23 9.72 ± 6.68 6.97 ± 5.91 0.002010 9.42 ± 6.65 6.23 ± 5.46 0.000256
BMI (normal/overweigh/
obese)
175/42/21 44/12/9 131/30/12 0.22 78/23/10 97/19/11 0.49
Total cholesterol (mg/dl) 177.63 ± 39.36 190.63 ± 43.43 172 ± 36.67 0.005492 182.21 ± 42.76 173.63 ± 35.83 0.231844
LDL cholesterol (mg/dl) 96.98 ± 32.63 106.75 ± 34.17 93.31 ± 31.35 0.004647 100.20 ± 36.54 94.16 ± 28.63 0.442408
HDL cholesterol (mg/dl) 63.15 ± 16.50 63.24 ± 14.09 63.11 ± 17.35 0.732890 63.72 ± 17.29 62.65 ± 15.82 0.751899
Triglyceride (mg/dl) 88.30 ± 50.07 94.64 ± 55.04 85.92 ± 48.02 0.073305 91.81 ± 52.99 85.24 ± 47.36 0.226357
Microalbuminuria (positive/
negative in %)a
14/186 9/91 5/95 0.6965 2/98 8/92 0.0590
HbA1c IFCC mean (mmol/
mmol)
58 ± 15 59 ± 16 58 ± 14 0.925898 58 ± 14 58 ± 15 0.651159
Daily insulin dose (u/kg/day) 0.82 ± 0.23 0.85 ± 0.15 0.81 ± 0.25 0.1633 0.85 ± 0.23 0.80 ± 0.23 0.1030
Pubertal status (prepubertal/
pubertal/postpubertal)
20/85/133 6/22/37 14/63/96 0.9139 5/39/67 15/46/66 0.1080
Dipping (yes/no) 127/111 26/39 101/72 0.0113 NA NA NA
NA not applicable
a unknown in 38 cases
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male sex, non-dipping and total cholesterol level
(Table 5.). Even after correction for these variables, none
of the genetic factors showed any trend for significance
toward association with HT. Multivariate analysis of fac-
tors associated with the presence of non-dipping phenom-
enon showed that the only factor which was retained in the
model was the duration of diabetes—OR 1.09 (95 % CI
1.04–1.14; p = 0.0001). None of the analyzed genetic
polymorphisms showed any significant relation to non-
dipping. The impact of HbA1c was not statistically sig-
nificant in models testing the variable as a continuous or
dichotomous factor (all p values [0.5).
Discussion
The rapidly increasing morbidity of diabetes among chil-
dren in the last years and estimated continuation of this
trend in the future makes the studies concerning risk factors
for chronic complications extremely valuable. Indication of
the group with high risk of HT, especially in the pediatric
population, will give the chance for early prevention and
treatment. It is commonly known that diabetes and
increased BP potentiate each other as risk factors for severe
cardiovascular complications.
Our study confirmed that the most important clinical risk
factors for disturbances with BP in children and young
adults with DMT1 remain to be male sex, duration of dia-
betes and atherogenic lipid profile. This was confirmed both
in the univariate analysis and also in multivariate analysis
with logistic regressions. Patients that did not display a BP
dip in the night were shown to have twice increased risk of
development of HT. These agents are well-known param-
eters connected with HT, as well as identified risk factors
for endothelium damage and macroangiopathy [1, 20, 21].
In the recently published study, Lee et al. [22] have shown
that especially nocturnal HT is associated with increased
carotid intima-media thickness (cIMT). In Lee’s study, the
cIMT was significantly higher in the hypertensive group
than in the non-hypertensive group, and HDL cholesterol
concentration was significantly lower in the hypertensive
group than in the non-hypertensive group. Thus, ABPM
may be a useful method for detecting the macrovascular
complications of DMT1.
In the studies concerning the development of HT in
diabetic patients, clinical factors, such as poor metabolic
control, high daily insulin dose and overweight/obesity, are
usually, but not always, implicated as causative [23–25]. In
the present study, we have not found such an association,
probably because our patients were generally well/subop-
timally controlled. They have been intensively treated with
multiple injections or insulin pumps from the onset of
diabetes and extensively educated about the importance of
low insulin dosing, as is the standard of care in our centers.
In our study, the overweight/obese was observed more
frequently in the HT versus non-HT group (32 vs. 25 %),
but the differences were not significant. In our previous
study concerning diabetic normotensive patients, we have
noted positive correlations between mean BP and both
BMI and body composition—fat mass content [25].
Although BMI is commonly accepted as an easily available
indicator of obesity, we should remember that it depends
on not only fat but also on muscle mass. In the present
study, we have the predominance of hypertensive males, so
we can suspect that some of the older adolescents and
young men have higher BMI because of well developed
muscles. In this situation, our result should be treated with
a caution.
The group of patients selected for this study was very
diverse in terms of age, gender and disease duration, with
Table 3 ACE and RGS2 genotypes of participants in relation to HT and to non-dipping (p = NS)
Hypertension versus normal BP P value Non-dippers versus dippers P value
HT (?) (N = 65) HT (-) (N = 173) Non-dippers (N = 111) Dippers (N = 127)
ACE rs1800764 TT 22 (34 %) 55 (30 %) 0.8958 37 (33 %) 38 (30 %) 0.8479
CT 29 (45 %) 84 (49 %) 51 (46 %) 62 (49 %)
CC 14 (21 %) 36 (21 %) 23 (21 %) 27 (21 %)
ACE rs4459609 AA 25 (39 %) 60 (35 %) 0.8479 39 (35 %) 46 (36 %) 0.7153
AC 30 (46 %) 83 (48 %) 51 (46 %) 62 (49 %)
CC 10 (15 %) 30 (17 %) 21 (19 %) 19 (15 %)
ACE I/DD rs1799752 II 16 (25 %) 40 (23 %) 0.5194 25 (23 %) 31 (24 %) 0.8825
ID 19 (29 %) 64 (37 %) 38 (34 %) 45 (36 %)
DD 30 (46 %) 69 (40 %) 48 (43 %) 51 (40 %)
RGS2 rs2746071 AA 34 (52 %) 102 (59 %) 0.4404 62 (56 %) 74 (58 %) 0.5516
AG 23 (36 %) 58 (34 %) 41 (37 %) 40 (32 %)
GG 8 (12 %) 13 (8 %) 8 (7 %) 13 (10 %)
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confirmed clinical characteristics of HT present among
some of the subjects. We believe therefore that our subject
group was appropriately representative for genetic studies.
In our study, we have hypothesized that the genetic pre-
disposition for development of HT could be recognized
from the beginning of diabetes. We have assessed the
distribution of genes connected with increased risk of
higher BP, which we hypothesized would be observed
more frequently among the subjects with recognized/trea-
ted HT. The ACE genes have been assessed in relation to
HT and diabetic nephropathy for many years, but the
results of these studies are conflicting. The best known
gene variant association is the I/D polymorphism, in which
DD allele determines higher angiotensin level and there-
fore potentially higher BP [18, 26]. This observation has
been confirmed in many studies conducted in the general
population and among subjects with T2DM [6, 27, 28].
Studies performed in the pediatric population have shown
that allele DD in ACE polymorphism is associated with
higher BP in normotensive, normoalbuminuric diabetic
children in ABPM measurements [9, 29]. Similarly in our
previous study, when we have taken into account only
clinically normotensive and normoalbuminuric children,
we have proven that subjects in the DD genotype group had
significantly higher nocturnal BP in comparison with ID/II
genotype group, and this was also connected with lower
dipping [10]. However, in the present study, where we have
analyzed the BP in the group with HT and without HT, we
have not found a more frequent occurrence of the DD
genotype among patients with HT and non-dipping. Our
study is in agreement with the results of other researches,
who did not replicate the associations between the geno-
type of ACE genes and HT in children with T1DM [7, 8].
In addition to the I/D variant which was widely inves-
tigated, we chose to study another two SNP of ACE,
rs1800764 and rs4459609, because they were shown to
characterize the haplotypic structure of ACE in European
populations [25, 29]. However, to our knowledge, there had
not been any clinical studies in humans concerning these
SNPs in relation to BP. Our study has not confirmed any
association of the considered SNPs with HT or non-dipping
in the studied group of adolescents and young adults with
T1DM. An important point of our study was to analyze the
RGS2 gene polymorphisms in association with BP regu-
lation, as there is very little data on the topic. Genetic
changes in RGS2 have been proven to be associated with a
hypertensive phenotype in the Japanese and American
Black populations [13, 14]. Moreover, in the Sugimoto et al
[12] study concerning genetic influence on the response
to a hypertensive drug, out of the eighteen genes stud-
ied, only the A-638-G polymorphism of the RGS2 gene
showed an association with the HT phenotype. Homozy-
gosity to this polymorphism conferred the best response to
Table 4 Association between genotypes and blood pressure load
ACE (rs1800764) P value
TT CT CC
Daytime
SBP % up 5 (0–32) 8 (0–24) 5 (0–25) 0.9793
DBP % up 4 (0–13) 3 (0–12) 2 (0–9) 0.4926
Nighttime
SBP % up 8 (0–47) 8 (0–40) 12 (0–33) 0.7812
DBP % up 0 (0–9) 0 (0–13) 0 (0–13) 0.9555
ACE (rs4459609) P value
AA AC CC
Daytime
SBP % up 6 (0–32) 6 (0–24) 6 (0–24) 0.9184
DBP % up 3 (0–15) 3 (0–10) 3 (0–10) 0.7331
Nighttime
SBP % up 8 (0–40) 8 (0–41) 10 (0–35) 0.9982
DBP % up 0 (0–14) 0 (0–10) 5 (0–13) 0.2007
ACE (rs1799752) P value
DD ID II
Daytime
SBP % up 7 (0–27) 3 (0–24) 7 (0–23) 0.3412
DBP % up 5 (0–13) 2 (0–11) 3 (0–11) 0.2382
Nighttime
SBP % up 8 (0–47) 8 (0–31) 8 (0–40) 0.8030
DBP % up 0 (0–14) 0 (0–10) 0 (0–10) 0.7227
RGS2 (rs2746071) P value
AA AG GG
Daytime
SBP % up 7 (0–27) 5 (0–23) 6 (0–36) 0.7792
DBP % up 3 (0–12) 3 (0–10) 7 (0–24) 0.7840
Nighttime
SBP % up 8 (0–33) 8.5 (0–45) 9 (0–47) 0.9773
DBP % up 0 (0–10) 0 (0–12) 7 (0–20) 0.3425
Values within the table represent the percentages of daytime and
nighttime systolic and diastolic blood pressure above normal range
for age, sex and height percentile
Table 5 Multivariate analysis of factors predisposing to HT
OR 95 % CI p
Male gender 1.623 1.171–2.250 0.003644
Non-dipper 1.402 1.034–1.902 0.029581
Total cholesterol 1.013 1.005–1.021 0.001099
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azelnidipine—a studied antihypertensive drug. Addition-
ally, Kamide et al [30] have established the association of
exactly this polymorphism with significant intima-media
thickening of the carotid artery both in hypertensive pop-
ulation and general population in humans. In our study,
homozygosity for the A-638-G RGS2 polymorphism was
present relatively frequently—in above 50 % of cases,
which could potentially be a therapeutic indication in HT
treatment and atherosclerosis development. However, the
aim of our study was to identify a hypertensive and non-
dipping genotype, and such genotype has not been
identified.
Our study does have some limitations, resulting from its
design and availability of data. Firstly, we were not able to
examine the patients for the presence of autonomic neu-
ropathy. This complication is directly linked to non-dip-
ping, and it is likely that at least some non-dipping patients
had developed neuropathy before the ABPM examination.
However, the database of patients enrolled in the study
included general information about the possible manifes-
tations of autonomic neuropathy, and none of the patients
reported such symptoms. Secondly, we analyzed two major
factors responsible for the development of neuropathy:
duration of diabetes and metabolic control (expressed as
HbA1c level) as continuous variables. It is possible that a
threshold of, for example 10 years of 9.0 % of HbA1c
would prove a strong risk factor and evidence an effect
unseen in a model testing these variables as continuous
ones. To account for that, we have performed ancillary
analyses with models for HT and non-dipping risks testing
HbA1c and duration of diabetes as dichotomous factors.
However, since no evidence of any nonlinear effects for
both variables were noted, we considered them as contin-
uous in the final analyses. Thirdly, the study was under-
powered to perform subgroup analyses in children differing
by pubertal stage. Although this factor did not prove sig-
nificant in univariate and multivariate analyses, it may be
possible that in pubertal patients, different factors may
determine the risk of HT or non-dipping than in other
groups, due to rapid hormonal changes. Finally, the mul-
tivariate model for HT showed that it was more frequent in
non-dippers. This may be interpreted in both directions—
with non-dipping predisposing to HT or HT provoking a
measurement bias for non-dipping due to increased night-
time BP. Nevertheless, since in our cohort more than 40 %
of patients with HT showed dipping, and 42 % of patients
without HT were non-dippers, we retained this factor in the
analysis as both were not mutually exclusive.
Concluding, in our study we have proven that in subjects
with good/suboptimal metabolic control of diabetes, some
clinical factors can be associated with the development of
HT: male sex, atherogenic lipid profile and the presence of
non-dipping. Furthermore, the non-dipping phenomenon is
mainly dependent on the duration of diabetes, which
decreases the odds of persistent dipping. Despite the
identification of groups with confirmed clinical HT/dipping
relationships, suggesting our study population was repre-
sentative of those groups, we have not managed to confirm
that the genetic variations in the ACE genotype—insertion/
deletion (rs17997552), rs1800764, rs4459609—and RGS2
rs2746071 genotype could be connected with the regula-
tion of the BP and lead to the disturbances in both HT and/
or non-dipping. It is possible that we have not managed to
elucidate any relationship due to the young age of our
subjects or the sample size being too small to demonstrate a
weak effect of genetic predisposition.
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